Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Leases: 2020-2025

Historic Capital Leases for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $3.2 million.

  • SAB Biotherapeutics' Capital Leases fell 4.56% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 4.56%. This contributed to the annual value of $3.3 million for FY2024, which is 4.17% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Capital Leases stood at $3.2 million for Q3 2025, which was down 1.21% from $3.2 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Capital Leases high stood at $3.8 million for Q4 2021, and its period low was $3.2 million during Q3 2025.
  • Its 3-year average for Capital Leases is $3.4 million, with a median of $3.3 million in 2024.
  • Data for SAB Biotherapeutics' Capital Leases shows a maximum YoY dropped of 5.90% (in 2024) over the last 5 years.
  • SAB Biotherapeutics' Capital Leases (Quarterly) stood at $3.8 million in 2021, then decreased by 3.53% to $3.6 million in 2022, then decreased by 5.82% to $3.4 million in 2023, then fell by 4.17% to $3.3 million in 2024, then fell by 4.56% to $3.2 million in 2025.
  • Its Capital Leases stands at $3.2 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.2 million for Q1 2025.